DOCSLIB.ORG

100 Storage Condition=50 C/Ambrh

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
100 Storage Condition=50 C/Ambrh USOO595.5058A United States Patent (19) 11 Patent Number: S.9SS,0589 9 Jager et al. (45) Date of Patent: Sep. 21,9 1999 54). STABILIZED MEDICINAL AEROSOL 56) References Cited SOLUTION FORMULATIONS CONTAINING U.S. PATENT DOCUMENTS IPRATROPIUM BROMIDE a 5,118,494 6/1992 Schultz et al. ............................ 424/45 75 Inventors: Paul Donald Jager, Waterbury; Mark 5,190,029 3/1993 Byron et al. ... ... 128/200.14 James Kontny, New Milford, both of 5,225,183 7/1993 Purewal et al. ........................... 424/45 Conn.; Jurgen Hubert Nagel 5.439,670 8/1995 Purewal et al. ... 424/45 Ingelheim/Rhein, Germany s 5,605,674 2/1997 Purewal et al. ........................... 424/45 FOREIGN PATENT DOCUMENTS 73 Assignee: Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, 0372 777 6/1990 European Pat. Off.. Conn. Primary Examiner Raj Bawa Attorney, Agent, or Firm Morgan & Finnegan, LLP 21 Appl.pp No.: 08/843,180 57 ABSTRACT 22 Filed: Apr. 14, 1997 Stabilized medicinal aeroSol Solution formulations compris O O ing medicaments that degrade or decompose by interaction Related U.S. Application Data with solvents or water, an HFC propellant, a cosolvent and an acid are described. Further, Specific medicinal aeroSol 63 Staggypt.NE "A iGs Solution formulations comprising ipratropium bromide or No. 08/153.549, Nov. 22, 1993, abandoned E. is a fenoterol, ethyl alcohol, 1,1,1,2-tetrafluoroethane or 1,1,1, continuation-in-part of application No. 07/987,852, Dec. 9, 2,3,3,3-heptafluoropropane, and either an inorganic acid or 1992, abandoned. an organic acid are described. The acids are present in 51 Int. CI. A61K 9/12 amounts Sufficient to reduce the degradation of the medica 52) US C - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 424/45. 424/46 ments to acceptable levels. 58 Field of Search .......................................... 424/45, 46 28 Claims, 1 Drawing Sheet 100 STORAGE CONDITION=50 C/AMBRH 1000 90.0 80.0 700 -o-o-o- O% H2O/NO N2 600 A-AA 4% H2O/N2 500 -H- O% H2O/N2 ---- 4% 0.03M HCI/N2 400 300 200 OO OO O 4 2 3 4. 5 6 STORAGE TIME (MONTHS) U.S. Patent Sep. 21, 1999 5,955,058 100 STORAGE CONDITION=50 C/AMBRH 1000 90.0 8O.O 700 -O-O-O-O% H2O/NO N2 60.O A-AA H2O/N2 500 -H- O% H2O/N2 ---- 4%, O.O3M HCI/N2 40.0 300 2O.O OO OO O 4 2 3 4. 5 6 STORAGE TIME (MONTHS) FIG. 5,955,058 1 2 STABILIZED MEDICINALAEROSOL route. Also, PCT Published Application No. WO91/11496 SOLUTION FORMULATIONS CONTAINING (PCT/EP91/00178) discloses the use of 1,1,1,2,3,3,3- IPRATROPIUM BROMIDE heptafluoropropane (HFC-227), optionally mixed with other propellant components, for use in preparing Suspension This application is a continuation of U.S. Ser. No. 5 aeroSol formulations of medicaments. 08/475,060, Jun. 7, 1995, now U.S. Pat. No. 5,676,930 It has now been found that the use of propellant Systems which is a continuation of U.S. Ser. No. 08/153,549, Nov. containing an HFC and a coSolvent in aeroSol Solution 22, 1993, abandoned, which is a continuation-in-part of U.S. formulations presents a chemical Stability problem that has Ser. No. 07/987,852, Dec. 9, 1992, abandoned. not been previously recognized or resolved in the prior art. This invention relates to Stable pharmaceutical Solution This is because in such HFC propellant/cosolvent systems, formulations Suitable for aerosol administration. More the medicament may interact with the coSolvent and/or particularly, this invention relates to stable pharmaceutical water present in the System to produce decomposition or Solution formulations Suitable for aerosol administration degradation products. It has now further been found that the wherein either an inorganic acid or an organic acid is added addition of an acid, either an inorganic acid or an organic to the aeroSol Solution formulation which contains a medi 15 acid, to the HFC propellant/cosolvent system provides the cament in Solution with an environmentally Safe hydrofluo requisite chemical Stability to the medicament. rocarbon (HFC) as a propellant, together with an organic compound as a coSolvent. The acid provides Stability against BRIEF DESCRIPTION OF THE DRAWING degradation or decomposition of the medicament resulting largely from interaction of the medicament with the cosol FIG. 1 depicts the stability profiles of ipratropium bro vent and/or water present in the Solution formulation. mide aeroSol Solutions. DESCRIPTION OF THE INVENTION BACKGROUND OF THE INVENTION The administration of aerosol formulations of medica The term “aeroSol Suspension formulation” means a phar ments by means of pressurized, metered-dose inhalers 25 maceutical formulation of a medicament Suitable for aeroSol (MDIs) is used widely in therapy, such as in the treatment of administration wherein the medicament is Suspended, in the obstructive airway diseases and asthma. Compared with oral form of finely, divided particles, in an excipient. administration, inhalation provides more rapid onset of The term “aerosol solution formulation” means a phar action while minimizing Systemic side effects. AeroSol for maceutical formulation of a medicament Suitable for aeroSol mulations can be administered by inhalation through the administration wherein the medicament and excipients are mouth or topically by application to the nasal mucosa. completely dissolved. Formulations for aerosol administration via MDIS can be The term “stabilized aerosol Solution formulation” means Solutions or Suspensions. Solution formulations offer the an aerosol Solution formulation which exhibits substantial chemical Stability over time. advantage of being homogeneous in nature with the medi 35 cament and excipient completely dissolved in the propellant Ipratropium bromide is an anticholinergic bronchodilator vehicle. Solution formulations also obviate physical stability marketed under the trademark “ATROVENT. This medi problems associated with Suspension formulations and thus cament is administered as an aeroSol Suspension formulation assure more consistent uniform dosage administration while which contains a mixture of CFCs also eliminating the need for Surfactants. 40 (dichlorodifluoromethane, dichlorctetrafluoroethane, and The administration of aeroSol Solution formulations via trichloromonofluoromethane) as the propellant, and Soya MDIs is dependent upon the propulsive force of the propel lecithin. lant System used in its manufacture. Traditionally, the pro Studies have demonstrated that stable aerosol Solution pellant comprised a mixture of chlorofluorocarbons (CFCs) formulations of ipratropium bromide can be obtained by to provide the desired Solubility, vapor pressure, and Stabil 45 dissolving ipratropium bromide in a homogeneous System ity of the formulation. However, since it has been estab comprising HFC-134(a), ethanol, and either an inorganic lished in recent years that CFCs are environmentally harm acid or an organic acid. The particular type and amount of ful because they contribute to the depletion of the Earth's acid added to the system will define the level of acidity oZone layer, it is desirable to Substitute environmentally Safe which is critical in obtaining a Stable Solution formulation. hydrofluorocarbon (HFC) propellants or other non 50 Thus, the present invention provides Stabilized aeroSol chlorinated propellants for environmentally harmful CFC Solution formulations comprising a medicament, an HFC propellants in aerosol inhalation formulations. For example, propellant, a coSolvent, and an inorganic acid or an organic U.S. Pat. No. 4,174,295 discloses the use of propellant acid. A small amount of water (up to about 5% by weight) Systems consisting of combinations of HFCs, which may may also be present in the propellant/coSolvent System. also contain a Saturated hydrocarbon component, Suitable 55 Suitable HFC propellants are those which, when mixed for application in the fields of home products Such as hair with the cosolvent(s), form a homogeneous propellant Sys lacquers, anti-perspiration products, perfumes, deodorants, tem in which a therapeutically effective amount of the paints, insecticides and the like. medicament can be dissolved. The HFC propellant must be It is known in the art that certain HFCs have properties toxicologically Safe and must have a vapor pressure which Suitable for use as propellants for the aerosol administration 60 is Suitable to enable the medicament to be administered via of medicaments. For example, published European patent a pressurized MDI. Additionally, the HFC propellant must Application No. 0372 777 (EPO89312270.5) describes the be compatible with the components of the MDI device (such use of 1,1,1,2-tetrafluoroethane (HFC-134(a)) in combina as containers, valves, and Sealing gaskets, etc.) which is tion with at least one “adjuvant” (a compound having a employed to administer the medicament. Preferred HFC higher polarity than the HFC-134(a)) and a surface active 65 propellants are 1,1,1,2-tetrafluoroethane (HFC-134(a)) and agent to prepare Suspension and Solution formulations of 1,1,1,2,3,3,3-heptafluoropropane (HFC-227). HFC-134(a) is medicaments Suitable for administration by the aeroSol particularly preferred. Other examples of HFC propellants 5,955,058 3 4 are HFC-32 (difluoromethane), HFC-143(a) (1,1,1- for use in the aeroSol Solution formulations of the present trifluoroethane), HFC-134 (1,1,2,2-tetrafluoroethane), and invention. Those skilled in the art will recognize that other HFC-152a (1,1-difluoroethane). classes of medicaments can in general be used. Examples of It will be apparent
Load more

Recommended publications
  • Dosing Time Matters
    bioRxiv preprint doi: https://doi.org/10.1101/570119; this version posted March 21, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Dosing Time Matters 1 2,3 4,5,6 1* Marc D. Ruben ,​ David F. Smith ,​ Garret A. FitzGerald ,​ and John B. Hogenesch ​ ​ ​ ​ 1 Division​ of Human Genetics, Center for Chronobiology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, 240 Albert Sabin Way, Cincinnati, OH, 45229 2 Divisions​ of Pediatric Otolaryngology and Pulmonary and Sleep Medicine, Cincinnati Children’s Hospital Medical Center, 3333 Burnet Ave, Cincinnati, OH 45229 3 Department​ of Otolaryngology-Head and Neck Surgery, University of Cincinnati School of Medicine, 231 Albert Sabin Way, Cincinnati, OH, 45267 4 Department​ of Systems Pharmacology and Translational Therapeutics, at the University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104 USA 5 Department​ of Medicine, at the University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104 USA 6 ​ Institute for Translational Medicine and Therapeutics (ITMAT), at the University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104 USA *Corresponding Author. Email: [email protected] Abstract Trainees in medicine are taught to diagnose and administer treatment as needed; time-of-day is rarely considered. Yet accumulating evidence shows that ~half of human genes and physiologic functions follow daily rhythms. Circadian medicine aims to incorporate knowledge of these rhythms to enhance diagnosis and treatment.
    [Show full text]
  • 18 December 2020 – to Date)
    (18 December 2020 – to date) MEDICINES AND RELATED SUBSTANCES ACT 101 OF 1965 (Gazette No. 1171, Notice No. 1002 dated 7 July 1965. Commencement date: 1 April 1966 [Proc. No. 94, Gazette No. 1413] SCHEDULES Government Notice 935 in Government Gazette 31387 dated 5 September 2008. Commencement date: 5 September 2008. As amended by: Government Notice R1230 in Government Gazette 32838 dated 31 December 2009. Commencement date: 31 December 2009. Government Notice R227 in Government Gazette 35149 dated 15 March 2012. Commencement date: 15 March 2012. Government Notice R674 in Government Gazette 36827 dated 13 September 2013. Commencement date: 13 September 2013. Government Notice R690 in Government Gazette 36850 dated 20 September 2013. Commencement date: 20 September 2013. Government Notice R104 in Government Gazette 37318 dated 11 February 2014. Commencement date: 11 February 2014. Government Notice R352 in Government Gazette 37622 dated 8 May 2014. Commencement date: 8 May 2014. Government Notice R234 in Government Gazette 38586 dated 20 March 2015. Commencement date: 20 March 2015. Government Notice 254 in Government Gazette 39815 dated 15 March 2016. Commencement date: 15 March 2016. Government Notice 620 in Government Gazette 40041 dated 3 June 2016. Commencement date: 3 June 2016. Prepared by: Page 2 of 199 Government Notice 748 in Government Gazette 41009 dated 28 July 2017. Commencement date: 28 July 2017. Government Notice 1261 in Government Gazette 41256 dated 17 November 2017. Commencement date: 17 November 2017. Government Notice R1098 in Government Gazette 41971 dated 12 October 2018. Commencement date: 12 October 2018. Government Notice R1262 in Government Gazette 42052 dated 23 November 2018.
    [Show full text]
  • Validation of New Analytical Methodology for Determining Fenoterolhydrobromide by HPLC: Application in Pharmaceutical Products
    Artigo Original/Original Article Validation of new analytical methodology for determining fenoterolhydrobromide by HPLC: application in pharmaceutical products Validação de uma nova metodologia analítica para determinação de bromidrato de fenoterol por CLAE: aplicações em produtos farmacêuticos RIALA6/1475 *Helena Miyoco YANO1, Fernanda Fernandes FARIAS1, Marcelo Beiriz DEL BIANCO1, Pedro Lopez GARCIA2 *Endereço para correspondência: 1Núcleo de Ensaios Físicos e Químicos em Medicamentos, Centro de Medicamentos, Cosméticos e Saneantes, Instituto Adolfo Lutz, Av. Doutor Arnaldo, 355, CEP: 01246-902, São Paulo, SP, Brasil. E-mail: [email protected] 2Departamento de Farmácia, Faculdade de Ciências Farmacêuticas, Universidade de São Paulo, São Paulo, SP, Brasil. Recebido: 31.10.2011- Aceito para publicação: 20.04.2012 RESUMO Bromidrato de fenoterol é um agente agonista adrenérgico β2-seletivo utilizado para tratamento de asma e doenças pulmonares crônicas obstrutivas. A metodologia analítica por cromatografia líquida de alta eficiência (CLAE) foi desenvolvida e validada para a determinação quantitativa de bromidrato de fenoterol. A condição analítica empregada incluiu coluna em fase reversa C18 (150 mm × 3,9 mm d.i., 5 µm) Thermo®, fase móvel composta de mistura de acetonitrila e água (30:70, v/v) com 0,1% de trietilamina e pH ajustado para 5,0 com ácido fórmico, vazão de 1,0 mL.min-1 e detecção em UV a 276 nm. A faixa de linearidade foi de 0,025 a 0,15 mg.mL-1; a curva analítica mostrou coeficiente de correlação > 0,999. O limite de detecção (LD) foi de 0,003 mg.mL-1 e o limite de quantificação de 0,012 mg.mL-1.
    [Show full text]
  • Ep 2560611 B1
    (19) TZZ Z___T (11) EP 2 560 611 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 9/00 (2006.01) 03.01.2018 Bulletin 2018/01 (86) International application number: (21) Application number: 11719211.2 PCT/EP2011/056227 (22) Date of filing: 19.04.2011 (87) International publication number: WO 2011/131663 (27.10.2011 Gazette 2011/43) (54) "PROCESS FOR PROVIDING PARTICLES WITH REDUCED ELECTROSTATIC CHARGES" VERFAHREN ZUR BEREITSTELLUNG VON PARTIKELN MIT REDUZIERTEN ELEKTROSTATISCHEN LADUNGEN PROCÉDÉ DE PRÉPARATION DE PARTICULES AYANT DES CHARGES ÉLECTROSTATIQUES RÉDUITES (84) Designated Contracting States: • GUCHARDI ET AL: "Influence of fine lactose and AL AT BE BG CH CY CZ DE DK EE ES FI FR GB magnesium stearate on low dose dry powder GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO inhaler formulations", INTERNATIONAL PL PT RO RS SE SI SK SM TR JOURNAL OF PHARMACEUTICS, ELSEVIER BV, NL LNKD- DOI:10.1016/J.IJPHARM.2007.06.041, (30) Priority: 21.04.2010 EP 10160565 vol. 348, no. 1-2, 19 December 2007 (2007-12-19), pages 10-17, XP022393884, ISSN: 0378-5173 (43) Date of publication of application: • ELAJNAF A ET AL: "Electrostatic 27.02.2013 Bulletin 2013/09 characterisation of inhaled powders: Effect of contact surface and relative humidity", (73) Proprietor: Chiesi Farmaceutici S.p.A. EUROPEAN JOURNAL OF PHARMACEUTICAL 43100 Parma (IT) SCIENCES, ELSEVIER, AMSTERDAM, NL LNKD- DOI:10.1016/J.EJPS.2006.07.006, vol. 29, no. 5, 1 (72) Inventors: December 2006 (2006-12-01), pages 375-384, • COCCONI, Daniela XP025137181, ISSN: 0928-0987 [retrieved on I-43100 Parma (IT) 2006-12-01] • MUSA, Rossella • CHAN ET AL: "Dry powder aerosol drug I-43100 Parma (IT) delivery-Opportunities for colloid and surface scientists", COLLOIDS AND SURFACES.
    [Show full text]
  • ADD/ADHD: Strattera • Allergy/Anti-Inflammatories
    EXAMPLES OF PERMITTED MEDICATIONS - 2015 ADD/ADHD: Strattera Allergy/Anti-Inflammatories: Corticosteroids, including Decadron, Depo-Medrol, Entocort, Solu-Medrol, Prednisone, Prednisolone, and Methylprednisolone Anesthetics: Alcaine, Articadent, Bupivacaine HCI, Chloroprocaine, Citanest Plain Dental, Itch-X, Lidocaine, Marcaine, Mepivacaine HCI, Naropin, Nesacaine, Novacain, Ophthetic, Oraqix, Paracaine, Polocaine, Pontocaine Hydrochloride, PrameGel, Prax, Proparacaine HCI, Ropivacaine, Sarna Ultra, Sensorcaine, Synera, Tetracaine, Tronothane HCI, and Xylocaine Antacids: Calci-Chew, Di-Gel, Gaviscon, Gelusil, Maalox, Mintox Plus, Mylanta, Oyst-Cal 500, Rolaids, and Tums Anti-Anxiety: Alprazolam, Atarax, Ativan, Buspar, Buspirone HCI, Chlordiazepoxide HCI, Clonazepam, Chlorazepate Dipotassium, Diastat, Diazepam, Hydroxyzine, Klonopin, Librium, Lorazepam, Niravam, Tranxene T-tab, Valium, Vistaril, and Xanax Antibiotics: Acetasol HC, Amoxil, Ampicillin, Antiben, Antibiotic-Cort, Antihist, Antituss, Avelox, Ceftazidime, Ceftin, Cefuroxime Axetil, Ceptaz, Cleocin, Cloxapen, Cortane-B Aqueous, Cortic, Cresylate, Debrox, Doryx, EarSol-HC, Fortaz, Gantrisin, Mezlin, Moxifloxacin, Neotic, Otocain, Principen, Tazicef, Tazidime, Trioxin, and Zyvox Anti-Depressants: Adapin, Anafranil, Asendin, Bolvidon, Celexa, Cymbalata, Deprilept, Effexor, Elavil, Lexapro, Luvox, Norpramin, Pamelor, Paxil, Pristiq, Prozac, Savella, Surmontil, Tofranil, Vivactil, Wellbutrin, Zoloft, and Zyban Anti-Diabetics: Actos, Amaryl, Avandia, Glipizide, Glucophage,
    [Show full text]
  • COVID-19 Evidence Bulletin 8
    COVID-19 Evidence Bulletin 8 Public Health England PHE International Epidemiology Daily Evidence Digest – 22nd April 2020 – 21st April 2020 – 20th April 2020 NICE COVID-19 rapid guideline: acute myocardial injury [NG171] Published 23rd April The purpose of this guideline is to help healthcare professionals who are not cardiology specialists identify and treat acute myocardial injury and its cardiac complications in adults with known or suspected COVID-19 but without known pre-existing cardiovascular disease. COVID-19 rapid guideline: gastrointestinal and liver conditions treated with drugs affecting the immune response [NG172] Published 23rd April The purpose of this guideline is to maximise the safety of children and adults who have gastrointestinal or liver conditions treated with drugs affecting the immune response during the COVID 19 pandemic. It also aims to protect staff from infection and enable services to make the best use of NHS resources. COVID-19 rapid guideline: managing symptoms (including at the end of life) in the community Published 3rd April, Last updated 22nd April NHS England Specialty Guides: Clinical guide for acute kidney injury in hospitalised patients with COVID-19 outside the intensive care unit during the coronavirus pandemic (22nd April - updated) Management of palliative care in hospital during the coronavirus pandemic (22nd April – updated) Department of Health and Social Care Medicines that cannot be parallel exported from the UK (22nd April) 33 medicines have been added to the parallel export list and the
    [Show full text]
  • Nystatin Ofloxacin Orciprenaline Sulfate
    JP XV Ultraviolet-visible Reference Spectra 1619 Nystatin A solution prepared as follows: To 10 mg add 50.25 mL of a mixture of diluted methanol (4 in 5) and sodium hydroxide TS (200:1), dissolve by warming at not exceeding 509C,andadddilutedmethanol(4in5)tomake500 mL. Ofloxacin Asolutionin0.1mol/LhydrochloricacidTS(1in150,000) Orciprenaline Sulfate A solution in 0.01 mol/L hydrochloric acid TS (1 in 10,000) 1620 Ultraviolet-visible Reference Spectra JP XV Oxazolam A solution in ethanol (95) (1 in 100,000) Oxethazaine A solution in ethanol (95) (1 in 2500) Oxybuprocaine Hydrochloride An aqueous solution (1 in 100,000) JP XV Ultraviolet-visible Reference Spectra 1621 Oxycodone Hydrochloride Hydrate An aqueous solution (1 in 10,000) Oxymetholone A solution prepared as follows: To 5 mL of a solution in methanol (1 in 5000) add 5 mL of sodium hydroxide-methanol TS and methanol to make 50 mL. Oxytetracycline Hydrochloride Asolutionin0.1mol/LhydrochloricacidTS(1in50,000) 1622 Ultraviolet-visible Reference Spectra JP XV Oxytocin An aqueous solution (1 in 2000) Penbutolol Sulfate A solution in methanol (1 in 10,000) Pentazocine A solution in 0.01 mol/L hydrochloric acid TS (1 in 10,000) JP XV Ultraviolet-visible Reference Spectra 1623 Peplomycin Sulfate Asolutionpreparedasfollows:To4mgadd5mL of copper (II) sulfate TS, and dissolve in water to make 100 mL. Perphenazine 1 Asolutionin0.1mol/LhydrochloricacidTS(1in200,000) Perphenazine 2 A solution obtained by adding 10 mL of water to 10 mL of the solution for Perphenazine 1 1624 Ultraviolet-visible
    [Show full text]
  • Ep 2626065 A1
    (19) TZZ Z_T (11) EP 2 626 065 A1 (12) EUROPEAN PATENT APPLICATION published in accordance with Art. 153(4) EPC (43) Date of publication: (51) Int Cl.: A61K 31/137 (2006.01) A61K 31/135 (2006.01) 14.08.2013 Bulletin 2013/33 A61K 31/4704 (2006.01) A61K 31/58 (2006.01) A61K 31/56 (2006.01) A61K 9/12 (2006.01) (2006.01) (2006.01) (21) Application number: 11827927.2 A61K 9/14 A61P 11/06 (86) International application number: Date of filing: 01.02.2011 (22) PCT/CN2011/070883 (87) International publication number: WO 2012/041031 (05.04.2012 Gazette 2012/14) (84) Designated Contracting States: (72) Inventor: WU, Wei-hsiu AL AT BE BG CH CY CZ DE DK EE ES FI FR GB Taipei GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO Taiwan (TW) PL PT RO RS SE SI SK SM TR (74) Representative: Patentanwaltskanzlei WILHELM (30) Priority: 28.09.2010 CN 201010502339 & BECK Prinzenstrasse 13 (71) Applicant: Intech Biopharm Ltd. 80639 München (DE) Taipei (TW) (54) COMPOUND COMPOSITION FOR INHALATION USED FOR TREATING ASTHMA (57) An inhaled pharmaceutical composition con- tric way as a controller. The eccentric way control therapy tains primary active ingredients of beta2- agonist and cor- could create a low blood concentration period during the ticosteroids.The pharmaceuticalcompositions disclosed day and minimize the acute tolerance phenomenon (or in the present invention are to be inhaled by a patient so called tachyphylaxis) for bronchodilator - beta2-ago- when needed as a reliever, or administrated in an eccen- nists in treating asthma or other obstructive respiratory disorders.
    [Show full text]
  • Clenbuterol Elisa Kit Instructions Product #101219 & 101216 Forensic Use Only
    Neogen Corporation 944 Nandino Blvd., Lexington KY 40511 USA 800/477-8201 USA/Canada | 859/254-1221 Fax: 859/255-5532 | E-mail: [email protected] | Web: www.neogen.com/Toxicology CLENBUTEROL ELISA KIT INSTRUCTIONS PRODUCT #101219 & 101216 FORENSIC USE ONLY INTENDED USE: For the determination of trace quantities of Clenbuterol and/or other metabolites in human urine, blood, oral fluid. DESCRIPTION Neogen Corporation’s Clenbuterol ELISA (Enzyme-Linked ImmunoSorbent Assay) test kit is a qualitative one-step kit designed for use as a screening device for the detection of drugs and/or their metabolites. The kit was designed for screening purposes and is intended for forensic use only. It is recommended that all suspect samples be confirmed by a quantitative method such as gas chromatography/mass spectrometry (GC/MS). ASSAY PRINCIPLES Neogen Corporation’s test kit operates on the basis of competition between the drug or its metabolite in the sample and the drug- enzyme conjugate for a limited number of antibody binding sites. First, the sample or control is added to the microplate. Next, the diluted drug-enzyme conjugate is added and the mixture is incubated at room temperature. During this incubation, the drug in the sample or the drug-enzyme conjugate binds to antibody immobilized in the microplate wells. After incubation, the plate is washed 3 times to remove any unbound sample or drug-enzyme conjugate. The presence of bound drug-enzyme conjugate is recognized by the addition of K-Blue® Substrate (TMB). After a 30 minute substrate incubation, the reaction is halted with the addition of Red Stop Solution.
    [Show full text]
  • 5 August 2004 Version
    The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product. Before prescribing any product mentioned in this Register, healthcare professionals should consult prescribing information for the product approved in their country. Study No.: SAM 30020 Title: Efficacy and tolerability of the salmeterol/fluticasone 50/100 mcg combination Diskus, inhaled once daily in the evening, in comparison to the p.r.n. inhalation from the reproterol/sodium cromoglycate 0.5/ 1 mg combination MDI, as initial therapy for patients with mild asthma – a multicentre, randomised, open, parallel trial Rationale: The reproterol/sodium cromoglycate 0.5/ 1 mg combination is still widely used for the treatment of mild asthmatics. Usually, patients inhale the combination product from an MDI, and they adjust the dosage according to their asthma symptoms. Anti-inflammatory medication with an inhaled corticosteroid such as fluticasone is an alternative therapeutic option, and long-acting beta agonists can be used as bronchodilatory treatment. The study aimed to investigate whether the efficacy of the salmeterol/fluticasone 50/100-mcg combination (SFC), inhaled from the Diskus once daily in the evening, is superior to that of the PRN inhalation of the reproterol/sodium cromoglycate 0.5/ 1 mg combination (RS) from the metered dose inhaler. Phase: IV Study Period: 13 June 2002 to 27 June 2003 Study Design: This randomised, prospective, open, parallel group study had a total duration of ten weeks. There were two study periods: a run-in period of two weeks, and a treatment period of 8 weeks.
    [Show full text]
  • Diagnosis and Management of Asthma in Older Adults Sanjay Haresh Chotirmall, MD, Michael Watts, MD, Peter Branagan, MD, Ciaran F
    PROGRESS IN GERIATRICS Diagnosis and Management of Asthma in Older Adults Sanjay Haresh Chotirmall, MD, Michael Watts, MD, Peter Branagan, MD, Ciaran F. Donegan, MD, Allan Moore, MD, and Noel Gerard McElvaney, MD Despite comprehensive guidelines established by the Euro- from 6.5% to 17.0%.5 Death rates associated with asthma pean Global Initiative for Asthma and the U.S. National depend on patient age; in a group of patients aged 55 to 59, Asthma Education and Prevention Program on the diagno- the death rate was 2.8 per 100,000 people, whereas in sis and management of asthma, its mortality in older adults people aged 60 to 64, it was 4.2 per 100, 000.6 Diagnostic continues to rise. Diagnostic and therapeutic problems and therapeutic problems contribute to many patients being contribute to older patients being inadequately treated. The inadequately treated. Despite its importance in older pa- diagnosis of asthma rests on the history and characteristic tients, asthma is particularly difficult to diagnose in this age pulmonary function testing (PFT) with the demonstration group. Symptoms typical of asthma such as intermittent of reversible airway obstruction, but there are unique prob- wheezing, breathlessness, and cough can also indicate other lems in performing this test in older patients and in its in- respiratory problems in older patients, particularly chronic terpretation. This review aims to address the difficulties in obstructive pulmonary disease (COPD). Similarly, other performing and interpreting PFT in older patients because symptoms of asthma such as chest pain or tightness may of the effects of age-related changes in lung function on be due to nonpulmonary disease such as ischemic heart respiratory physiology.
    [Show full text]
  • Diamandis Thesis
    !"!#$ CHEMICAL GENETIC INTERROGATION OF NEURAL STEM CELLS: PHENOTYPE AND FUNCTION OF NEUROTRANSMITTER PATHWAYS IN NORMAL AND BRAIN TUMOUR INITIATING NEURAL PRECUSOR CELLS by Phedias Diamandis A thesis submitted in conformity with the requirements for the degree of Doctor of Philosophy. Department of Molecular Genetics University of Toronto © Copyright by Phedias Diamandis 2010 Phenotype and Function of Neurotransmitter Pathways in Normal and Brain Tumor Initiating Neural Precursor Cells Phedias Diamandis Doctor of Philosophy Department of Molecular Genetics University of Toronto 2010 &'(!)&*!% The identification of self-renewing and multipotent neural stem cells (NSCs) in the mammalian brain brings promise for the treatment of neurological diseases and has yielded new insight into brain cancer. The complete repertoire of signaling pathways that governs these cells however remains largely uncharacterized. This thesis describes how chemical genetic approaches can be used to probe and better define the operational circuitry of the NSC. I describe the development of a small molecule chemical genetic screen of NSCs that uncovered an unappreciated precursor role of a number of neurotransmitter pathways commonly thought to operate primarily in the mature central nervous system (CNS). Given the similarities between stem cells and cancer, I then translated this knowledge to demonstrate that these neurotransmitter regulatory effects are also conserved within cultures of cancer stem cells. I then provide experimental and epidemiologically support for this hypothesis and suggest that neurotransmitter signals may also regulate the expansion of precursor cells that drive tumor growth in the brain. Specifically, I first evaluate the effects of neurochemicals in mouse models of brain tumors. I then outline a retrospective meta-analysis of brain tumor incidence rates in psychiatric patients presumed to be chronically taking neuromodulators similar to those identified in the initial screen.
    [Show full text]